]>
IRCT20200304046698N1 IRCT 2020-04-09 Yazd University of Medical Sciences Effects of escitalopram and Citalopram on Depression in Patients with Chronic Kidney Failure under Hemodialysis Evaluation and comparison of the effects and complications of escitalopram and citalopram on depression in patients with chronic renal failure undergoing hemodialysis 2018-09-23 anticipated 50 Complete https://irct.ir/trial/46362 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The present study is a prospective, double-blind, randomized clinical trial. Patients according to the table of random numbers were assigned to receive either escitalopram or citalopram for 6 weeks, Blinding description: Patients participating in the design and principal investigator were kept blind to the assigned study groups.As the drugs were selected from a single drug company and in order to double-blind the study, the escitalopram and citalopram tablets were provided by the pharmacist in a completely similar capsules form drug to the patients and distributed to the patients based on the treatment group and with a confidential code. 3 Major depressive disorder, chronic renal failure. Intervention 1: The intervention group: In this group escitalopram is prescribed .escitalopram dose increased from 5 mg to 10 mg per day. The drugs were selected from Tehran Pharmaceutical Company and in order to double blind study,escitalopram tablets were provided by a pharmacist in capsule form and distributed to patients based on group therapy and confidential code. Patients' follow-up was performed after 6 weeks of treatment and after completing the course of re-treatment, Hamilton test was examined and drug side effects including: dry mouth, nausea, yawning, sweating, agitation, reduction Appetite, constipation, diarrhea, drowsiness, headache and sexual problems, According to the questionnaire was prepared by the researcher was measured. Intervention 2: The control group: In this group citalopram prescribed.The dose of the drug was increased from 10 mg to 20 mg per day.The drugs were selected from the drug company Poursina and in order to double blind study,citalopram tablets were provided by a pharmacist in capsule form and distributed to patients based on group therapy and confidential code.Patients' follow-up was performed after 6 weeks of treatment and after completing the course of re-treatment, Hamilton's test was examined and drug side effects including: dry mouth, nausea, yawning, sweating, agitation, reduction Appetite, constipation, diarrhea, drowsiness, headache and sexual problems, According to the questionnaire was prepared by the researcher was measured. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information
public mina ayatollahi
No. 50, Ershad eslami St., Safaiieh
yazd Iran (Islamic Republic of) 8916864651 +98 35 3824 0667 mina_6432@yahoo.com Yazd University of Medical Sciences scientific mina ayatolahi
No. 50, Ershad eslami St., Safaiieh
yazd Iran (Islamic Republic of) 8916864651 +98 35 3824 0667 mina_6432@yahoo.com Yazd University of Medical Sciences Iran (Islamic Republic of) Patients with major depressive disorder with minimum depression score of 13 with Hamilton Test and psychiatrist approval Patients with renal failure who have been undergoing hemodialysis treatment for at least 3 months 18 years 65 years Both Systemic medical disease (heart disease, diabetes, epilepsy, hypertension, thyroid) that interferes with medication use or follow-up. Liver failure, Hepatitis B and C, HIV / AIDS Existence of psychiatric disorder other than depression Patient being treated with SSRIs (if previously treated after 3 months treatment) Pregnancy or lactation Addiction to all kinds of drugs and psychotropics The occurrence of any unbearable side effects in the patient F34 Persistent mood [affective] disorders Treatment - Drugs Treatment - Drugs The intervention group: In this group escitalopram is prescribed .escitalopram dose increased from 5 mg to 10 mg per day. The drugs were selected from Tehran Pharmaceutical Company and in order to double blind study,escitalopram tablets were provided by a pharmacist in capsule form and distributed to patients based on group therapy and confidential code. Patients' follow-up was performed after 6 weeks of treatment and after completing the course of re-treatment, Hamilton test was examined and drug side effects including: dry mouth, nausea, yawning, sweating, agitation, reduction Appetite, constipation, diarrhea, drowsiness, headache and sexual problems, According to the questionnaire was prepared by the researcher was measured. The control group: In this group citalopram prescribed.The dose of the drug was increased from 10 mg to 20 mg per day.The drugs were selected from the drug company Poursina and in order to double blind study,citalopram tablets were provided by a pharmacist in capsule form and distributed to patients based on group therapy and confidential code.Patients' follow-up was performed after 6 weeks of treatment and after completing the course of re-treatment, Hamilton's test was examined and drug side effects including: dry mouth, nausea, yawning, sweating, agitation, reduction Appetite, constipation, diarrhea, drowsiness, headache and sexual problems, According to the questionnaire was prepared by the researcher was measured. Depression score on the Hamilton scale. Timepoint: Assessment of Hamilton depression score at baseline and 6 weeks after intervention. Method of measurement: Hamilton Depression Inventory. Drug side effect. Timepoint: At baseline (before intervention) and 6 weeks after drug administration. Method of measurement: Questionnaire designed by the researcher. Shahid Sadoughi University of Medical Sciences Approved 2019-01-25 IR.SSU.MEDICINE.REC No. 50, molasadra, ershad eslami street, yazs Town, yazd Yazd Iran (Islamic Republic of)